Condition: Hemophilia A · Sponsor: Washington Institute for Coagulation
The investigators propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A. Per current standard of care, most patients are on prophylactic FVIII replacement therapy intravenously several times weekly with a goal of keeping the trough \>1% FVIII. Recent phase 3 data suggest superior bleed protection with emicizumab prophylaxis every 1-2 weeks. It is the purpose of this study to longitudinally assess joint health and bone density over 3 years and to compare the effect of routine factor VIII prophylaxis with emicizumab prophylaxis.
This description comes directly from the study's public registry record.
Rebecca Kruse-Jarres, MD, MPH · 206-614-1200 · RKJ@WACBD.org
Cassandra Bryan · 206-681-9072 · cassandra.bryan@wacbd.org
Always discuss trial participation with your own doctor first.
| Orthopedic Hemophilia Treatment Center | Los Angeles, California, United States | Not Yet Recruiting |
| Hemophilia and Thrombosis Treatment Center, University of California, San Diego | San Diego, California, United States | Recruiting |
| The University of Texas Health Science Center at San Antonio | San Antonio, Texas, United States | Recruiting |
| Washington Center for Bleeding Disorders at Washington Institute for Coagulation | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04131036